AU2725600A - Antagonist blockade of crf2 receptors for the treatment of psy chiatric disorders and the use of chimeric antisense oligonucleotides in (in vivo) cnsstudies of gene function - Google Patents

Antagonist blockade of crf2 receptors for the treatment of psy chiatric disorders and the use of chimeric antisense oligonucleotides in (in vivo) cnsstudies of gene function

Info

Publication number
AU2725600A
AU2725600A AU27256/00A AU2725600A AU2725600A AU 2725600 A AU2725600 A AU 2725600A AU 27256/00 A AU27256/00 A AU 27256/00A AU 2725600 A AU2725600 A AU 2725600A AU 2725600 A AU2725600 A AU 2725600A
Authority
AU
Australia
Prior art keywords
cnsstudies
psy
vivo
treatment
antisense oligonucleotides
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Abandoned
Application number
AU27256/00A
Inventor
Siew Peng Ho
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Bristol Myers Squibb Pharma Co
Original Assignee
DuPont Merck Pharmaceutical Co
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by DuPont Merck Pharmaceutical Co filed Critical DuPont Merck Pharmaceutical Co
Publication of AU2725600A publication Critical patent/AU2725600A/en
Abandoned legal-status Critical Current

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
    • C12N15/09—Recombinant DNA-technology
    • C12N15/11—DNA or RNA fragments; Modified forms thereof; Non-coding nucleic acids having a biological activity
    • C12N15/113—Non-coding nucleic acids modulating the expression of genes, e.g. antisense oligonucleotides; Antisense DNA or RNA; Triplex- forming oligonucleotides; Catalytic nucleic acids, e.g. ribozymes; Nucleic acids used in co-suppression or gene silencing
    • C12N15/1138—Non-coding nucleic acids modulating the expression of genes, e.g. antisense oligonucleotides; Antisense DNA or RNA; Triplex- forming oligonucleotides; Catalytic nucleic acids, e.g. ribozymes; Nucleic acids used in co-suppression or gene silencing against receptors or cell surface proteins
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2310/00—Structure or type of the nucleic acid
    • C12N2310/30—Chemical structure
    • C12N2310/31—Chemical structure of the backbone
    • C12N2310/315—Phosphorothioates
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2310/00—Structure or type of the nucleic acid
    • C12N2310/30—Chemical structure
    • C12N2310/32—Chemical structure of the sugar
    • C12N2310/321—2'-O-R Modification
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2310/00—Structure or type of the nucleic acid
    • C12N2310/30—Chemical structure
    • C12N2310/34—Spatial arrangement of the modifications
    • C12N2310/346—Spatial arrangement of the modifications having a combination of backbone and sugar modifications
AU27256/00A 1999-01-13 2000-01-13 Antagonist blockade of crf2 receptors for the treatment of psy chiatric disorders and the use of chimeric antisense oligonucleotides in (in vivo) cnsstudies of gene function Abandoned AU2725600A (en)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US11574899P 1999-01-13 1999-01-13
US60115748 1999-01-13
PCT/US2000/000819 WO2000042178A2 (en) 1999-01-13 2000-01-13 Antagonist blockade of crf2 receptors for the treatment of psy chiatric disorders and the use of chimeric antisense oligonucleotides in in vivo cns studies of gene function

Publications (1)

Publication Number Publication Date
AU2725600A true AU2725600A (en) 2000-08-01

Family

ID=22363191

Family Applications (1)

Application Number Title Priority Date Filing Date
AU27256/00A Abandoned AU2725600A (en) 1999-01-13 2000-01-13 Antagonist blockade of crf2 receptors for the treatment of psy chiatric disorders and the use of chimeric antisense oligonucleotides in (in vivo) cnsstudies of gene function

Country Status (2)

Country Link
AU (1) AU2725600A (en)
WO (1) WO2000042178A2 (en)

Families Citing this family (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JP2002537792A (en) * 1999-03-05 2002-11-12 エピジェネシス ファーマシューティカルズ，アイエヌシー How to Validate / Invalidate Targets and Pathways
EP1558639A2 (en) * 2002-10-31 2005-08-03 Janssen Pharmaceutica N.V. Genes whose expression is increased in response to stimulation by corticotropin-releasing hormone
US20160138014A1 (en) * 2012-10-12 2016-05-19 Isis Pharmaceuticals, Inc. Antisense compounds and uses thereof

Family Cites Families (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
GB9518864D0 (en) * 1995-09-14 1995-11-15 Cambridge Res & Innovation Oligonucleotides and their uses

Also Published As

Publication number Publication date
WO2000042178A2 (en) 2000-07-20
WO2000042178A3 (en) 2000-11-30

Similar Documents

Publication Publication Date Title
HUP0200469A3 (en) Use of sulfamate derivatives for treating impulse control disorders
HU0003386D0 (en) Use of crf antagonists
IL157815A0 (en) Fused pyridine derivatives for use as vanilloid receptor antagonists for treating pain
HUP0203425A3 (en) Quinazoline derivatives, process for their preparation and their use
AU4193700A (en) Antisense oligonucleotide compositions and methods for the modulation of jnk proteins
AU6868698A (en) Graphical user interface for use with multiple electrode catheters
TW435208U (en) Disposable diaper
IL147655A0 (en) Applicator for use in reflexotherapy
TW475426U (en) Disposable diaper
IL147541A0 (en) Oligonucleotides for inhibiting the expression of human eg5
EP1228167B8 (en) Use of sulfur reduction agent in fluid catylytic cracking
SG82072A1 (en) Disposable diaper
TW468466U (en) Disposable diaper
HUP0003428A3 (en) Use of leptin antagonists for the treatment of diabetes
AU6228000A (en) The use of retinoid receptor antagonists in the treatment of prostate carcinoma
AU2001275707A1 (en) Use of panaxatriol for stimulation angiogenesis
AU2725600A (en) Antagonist blockade of crf2 receptors for the treatment of psy chiatric disorders and the use of chimeric antisense oligonucleotides in (in vivo) cnsstudies of gene function
AU5802800A (en) Form of administration for applying in body orifices
HUP0301553A3 (en) Pharmaceutical compositions and their use for treating neurological disorders
AU6094200A (en) Nor gene compositions and methods for use thereof
EP1242453A4 (en) Dna encoding snorf62 and snorf72 receptors
TW580908U (en) Disposable diaper
AU2003264297A1 (en) Use of vanilloid receptor antagonists for the treatment of pain
GB2346692B (en) Electro-optic probe
GB2348283B (en) Electro-optic probe

Legal Events

Date Code Title Description
MK6 Application lapsed section 142(2)(f)/reg. 8.3(3) - pct applic. not entering national phase